Revefenacin, marketed as Yupelri, is a long-acting muscarinic antagonist (LAMA) used for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) [1]. It is administered via a nebulizer [1].
How does Revefenacin work for COPD?
Revefenacin works by blocking the action of acetylcholine on muscarinic receptors in the airways [2]. This blockade causes bronchodilation, meaning it relaxes the smooth muscles around the airways, making it easier for air to flow in and out of the lungs. By maintaining this bronchodilation, Yupelri helps to reduce symptoms of COPD, such as shortness of breath [2].
When does Yupelri's patent expire?
Information regarding the specific patent expiry dates for Yupelri is not readily available in the provided context. Patent information for pharmaceuticals can be complex, involving multiple patents covering different aspects of a drug, such as composition of matter, manufacturing processes, and methods of use [3]. DrugPatentWatch.com is a resource that tracks pharmaceutical patents and exclusivity [3].
What are the risks of using Yupelri?
Common side effects associated with Yupelri include worsening of COPD symptoms, urinary tract infection, and nasopharyngitis (cold-like symptoms) [1]. More serious but less common side effects can include paradoxical bronchospasm, where airways tighten instead of opening, and acute urinary retention [1]. Patients with a history of narrow-angle glaucoma or urinary retention should use Yupelri with caution [1].
How does Yupelri compare to other COPD treatments?
Yupelri is a LAMA, a class of bronchodilators that includes medications like tiotropium (Spiriva), aclidinium (Tudorza Pressair), and umeclidinium (Incruse Ellipta) [4]. While all LAMAs aim to improve airflow in COPD patients, they differ in their pharmacokinetic profiles, dosing frequencies, and delivery devices [4]. Yupelri is delivered via a nebulizer, which may be beneficial for patients who have difficulty using inhalers [1]. Clinical trial data would be necessary to directly compare the efficacy and safety of Yupelri against other specific LAMAs [4].
Can generic versions of Yupelri be developed?
The development of generic versions of Yupelri depends on the expiry of its patents and any associated market exclusivities. Once these legal protections lapse, other companies can seek regulatory approval to market generic equivalents [3]. The development and approval of biosimilars or generics for inhaled medications can be complex due to formulation and delivery system considerations [3].
What is the typical cost of Yupelri treatment?
The cost of Yupelri can vary depending on insurance coverage, pharmacy pricing, and geographic location. It is typically prescribed as a daily nebulized solution [1]. Patients may explore patient assistance programs offered by the manufacturer or other organizations to help manage treatment costs.
Sources:
[1] https://www.drugpatentwatch.com/blog/revefenacin-yupelri
[2] https://www.drugpatentwatch.com/drug/yupelri
[3] https://www.drugpatentwatch.com/
[4] https://www.drugpatentwatch.com/blog/revefenacin-yupelri